Amprion’s Parkinson’s Disease Dx Shows Strong Performance in Study

360Dx, April 26, 2023

A study led by researchers with the Parkinson’s Progression Markers Initiative has found that alpha-synuclein seed amplification assay (αSyn-SAA) testing can diagnose the most common form of Parkinson’s disease with high accuracy...READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.